Product Portfolio

RHEI’s current product portfolio includes branded pharmaceuticals in oncology and dermatology. RHEI continually seeks late stage product opportunities to in-license.

Product Description Indication Licensor Commercial Parnter Time to Market
Drs. Hans Schreuder Scar treatment cream Dermatology Drs. Hans Schreuder PowerE2E Ltd
(Shanghai)
Approved
MugardTM Proprietary oral rinse product for the prevention and treatment of oral mucositis Oncology Access Pharmaceuticals Shenzhen Jian’An Pharmaceuticals Approved
Tixozin Zinc Oxide Spray Dermatology Oystershell Beijing King Health Investment Co 2013 Q4
TibozoleTM Muco-adhesive tablet for the treatment of oral candidiasis in immuno-depressed patients Oncology Tibotec Shenzhen Jian’An Pharmaceuticals 2015 Q1